Cytosorbents Corporation (CTSO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Phillip P. Chan M.D., Ph.D. | CEO & Director | 541.93k | -- | 1970 |
| Mr. Vincent J. Capponi M.S. | President & COO | 452.62k | -- | 1958 |
| Ms. Kathleen P. Bloch CPA, M.B.A. | Chief Financial Officer | 395.43k | -- | 1955 |
| Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D. | Chief Medical Officer | 463.15k | -- | 1968 |
| Ms. Terri Anne Powers M.B.A. | Vice President of Investor Relations & Corporate Communications | -- | -- | -- |
| Dr. Christian Steiner M.D. | Executive Vice President of Sales & Marketing | -- | -- | -- |
| Mr. Christopher Cramer M.B.A., M.S. | Senior Vice President of Business Development | -- | -- | -- |
| Dr. Irina B. Kulinets Ph.D. | Senior Vice President of Global Regulatory Affairs | -- | -- | 1955 |
| Jodi Hoover | Executive | -- | -- | -- |
| Dr. Robert H. Bartlett M.D. | Co-Chairman of Cardiac Surgery Advisory Board & Consultant | 54k | -- | 1939 |
Cytosorbents Corporation
- Sector:
- Healthcare
- Industry: Medical Devices
- Full Time Employees:
- 186
Description
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Corporate Governance
Recent Events
- Apr 03, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 15, 202410-K: Periodic Financial ReportsSee Full Filing
- Jan 17, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Dec 28, 20238-K: Corporate Changes & Voting MattersSee Full Filing
- Dec 13, 20238-K: Corporate Changes & Voting MattersSee Full Filing